Susan Smith - Y MAbs Senior Officer
| YMAB Stock | USD 11.92 0.04 0.34% |
Executive
Susan Smith is Senior Officer of Y mAbs Therapeutics
| Age | 53 |
| Address | 230 Park Avenue, New York, NY, United States, 10169 |
| Phone | 646 885 8505 |
| Web | https://www.ymabs.com |
Susan Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Susan Smith against Y MAbs stock is an integral part of due diligence when investing in Y MAbs. Susan Smith insider activity provides valuable insight into whether Y MAbs is net buyers or sellers over its current business cycle. Note, Y MAbs insiders must abide by specific rules, including filing SEC forms every time they buy or sell Y MAbs'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Susan Smith over three months ago Disposition of 5984 shares by Susan Smith of Centene Corp at 68.93 subject to Rule 16b-3 | ||
Susan Smith over three months ago Acquisition by Susan Smith of 35700 shares of Y MAbs at 9.83 subject to Rule 16b-3 | ||
Susan Smith over six months ago Acquisition by Susan Smith of 17800 shares of Y MAbs subject to Rule 16b-3 |
Y MAbs Management Efficiency
The company has return on total asset (ROA) of (0.1198) % which means that it has lost $0.1198 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2478) %, meaning that it created substantial loss on money invested by shareholders. Y MAbs' management efficiency ratios could be used to measure how well Y MAbs manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.18. In addition to that, Return On Capital Employed is expected to decline to -0.25. At present, Y MAbs' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 129.5 M, whereas Other Current Assets are forecasted to decline to about 4.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kathleen Farren | Merus BV | N/A | |
| Andrew McKibben | Mirum Pharmaceuticals | N/A | |
| Anne MD | Sutro Biopharma | 56 | |
| Charles Lin | Kronos Bio | 39 | |
| Jan Smith | Revolution Medicines | N/A | |
| Kendra Adams | C4 Therapeutics | N/A | |
| Sarah Alspach | Bluebird bio | N/A | |
| Gregory Perry | Merus BV | 64 | |
| Kevin McManus | Syndax Pharmaceuticals | 55 | |
| HansPeter Gerber | Sutro Biopharma | 61 | |
| MPH DO | Kronos Bio | 59 | |
| Sandra Gardiner | Kronos Bio | 58 | |
| Kathleen Borthwick | Passage Bio | 47 | |
| Mohan Bala | Mersana Therapeutics | 59 | |
| Andrew MD | Merus BV | 58 | |
| Ashley PharmD | Merus BV | N/A | |
| Jasmin Tower | Generation Bio Co | N/A | |
| Jennifer Johansson | Larimar Therapeutics | N/A | |
| Marc Damelin | Mersana Therapeutics | N/A | |
| Joanne MD | Mirum Pharmaceuticals | 60 | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
Management Performance
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.12 |
Y mAbs Therapeutics Leadership Team
Elected by the shareholders, the Y MAbs' board of directors comprises two types of representatives: Y MAbs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of YMAB. The board's role is to monitor Y MAbs' management team and ensure that shareholders' interests are well served. Y MAbs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Y MAbs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Courtney Dugan, Vice Relations | ||
| Susan Smith, Senior Officer | ||
| Thomas Gad, Chairman of the Board and Presidentident, Founder, Head of Business Development and Strategy | ||
| MBBS MBA, Senior Officer | ||
| Torben MSc, VP Operations | ||
| Michael Rossi, President CEO | ||
| Sue Smith, VP Officer | ||
| Peter CPA, CFO Treasurer | ||
| Joris Wilms, COO, Senior Vice President | ||
| MSc MD, Senior Officer | ||
| Bo Kruse, CFO, Treasurer, Secretary, Director | ||
| FACNP FACP, Chief Officer |
YMAB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Y MAbs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 466.84 M | ||||
| Shares Outstanding | 44.79 M | ||||
| Shares Owned By Insiders | 12.21 % | ||||
| Shares Owned By Institutions | 72.24 % | ||||
| Number Of Shares Shorted | 3.63 M | ||||
| Price To Book | 5.78 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.921 | Quarterly Revenue Growth (0.1) | Return On Assets (0.12) | Return On Equity (0.25) |
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.